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Health of Maternally HIV-Unexposed and Exposed
Zambian Infants: A Randomised Controlled Trial
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Abstract
Background: The period of complementary feeding, starting around 6 months of age, is a time of high risk for growth
faltering and morbidity. Low micronutrient density of locally available foods is a common problem in low income countries.
Children of HIV-infected women are especially vulnerable. Although antiretroviral prophylaxis can reduce breast milk HIV
transmission in early infancy, there are no clear feeding guidelines for after 6 months. There is a need for acceptable,
feasible, affordable, sustainable and safe (AFASS by WHO terminology) foods for both HIV-exposed and unexposed children
after 6 months of age.
Methods and Findings: We conducted in Lusaka, Zambia, a randomised double-blind trial of two locally made infant foods:
porridges made of flour composed of maize, beans, bambaranuts and groundnuts. One flour contained a basal and the
other a rich level of micronutrient fortification. Infants (n = 743) aged 6 months were randomised to receive either regime for
12 months. The primary outcome was stunting (length-for-age Z,22) at age 18 months. No significant differences were
seen between trial arms overall in proportion stunted at 18 months (adjusted odds ratio 0.87; 95% CI 0.50, 1.53; P = 0.63),
mean length-for-age Z score, or rate of hospital referral or death. Among children of HIV-infected mothers who breastfed
,6 months (53% of HIV-infected mothers), the richly-fortified porridge increased length-for-age and reduced stunting
(adjusted odds ratio 0.17; 95% CI 0.04, 0.84; P = 0.03). Rich fortification improved iron status at 18 months as measured by
hemoglobin, ferritin and serum transferrin receptors.
Conclusions: In the whole study population, the rich micronutrient fortification did not reduce stunting or hospital referral
but did improve iron status and reduce anemia. Importantly, in the infants of HIV-infected mothers who stopped
breastfeeding before 6 months, the rich fortification improved linear growth. Provision of such fortified foods may benefit
health of these high risk infants.
Trial registration: Controlled-Trials.com ISRCTN37460449
Citation: The Chilenje Infant Growth, Nutrition and Infection (CIGNIS) Study Team (2010) Micronutrient Fortification to Improve Growth and Health of Maternally
HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial. PLoS ONE 5(6): e11165. doi:10.1371/journal.pone.0011165
Editor: Patricia Kissinger, Tulane University, United States of America
Received November 17, 2009; Accepted May 12, 2010; Published June 17, 2010
Copyright:  2010 The Chilenje Infant Growth, Nutrition and Infection (CIGNIS) Study Team. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Main funder: Bill and Melinda Gates Foundation grant #37253. Contibution in kind (micronutrient premixes): DSM South Africa. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Suzanne.Filteau@lshtm.ac.uk
" Membership of The Chilenje Infant Growth, Nutrition and Infection (CIGNIS) Study Team is provided in the Acknowledgments.
Introduction
The period of complementary feeding is a period of high risk for
growth faltering which may result in permanent stunting and its
adverse health consequences. [1] Although there has been some
progress in promoting and supporting exclusive breastfeeding, [2]
programmes addressing complementary feeding [3] in the second
half of infancy and early childhood have yet to meet with similar
success.
Infant and young child feeding practices are further complicated
in HIV-endemic sub-Saharan Africa. HIV-exposed infants, even if
not themselves infected, are at increased risk of poor growth and
death; mechanisms are unclear but likely involve nutrition [4].
HIV-infected women are advised to exclusively breastfeed their
infants unless they have access to replacement foods which are
acceptable, feasible, affordable, sustainable and safe (AFASS; [5]).
Recent studies have shown that providing antiretroviral drugs to
women or infants for the first few months after delivery can reduce
breast milk transmission of HIV [6]. However, it remains unclear
when to stop these antiretrovirals in women who do not yet need
them for their own health and when HIV-infected women should
stop breastfeeding. Given the continuing transmission risk
throughout breastfeeding [6], many HIV-infected women wish
to stop early, especially if their infant is HIV-negative at around 6
months old. Furthermore, after about 6 months, other foods need
to be introduced to the infant’s diet, whether or not the mother
continues to breastfeed [3]. Unfortunately, in much of sub-
Saharan Africa available foods for infants are grossly inadequate
whether they are fed as complementary foods or as replacement
foods in the absence of breastfeeding [4,7,8].
A major problem with available infant foods is low micronu-
trient density. [9] Micronutrient deficiencies are common in
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Zambia. [10,11] Micronutrient-rich foods are often expensive and
fortification of widely consumed foods may be a more effective
intervention to improve micronutrient status than promotion of
consumption of foods naturally rich in micronutrients. Further-
more, central fortification requires less active consumer participa-
tion than micronutrient supplementation and is not associated
with adverse effects seen with some supplements, notably iron
[12]. Zambia has a track record of successful implementation of
universal fortification of sugar with vitamin A and salt with iodine.
[10,13] There have been plans to fortify the staple, maize, with
several micronutrients. [10] However, the fortificant levels for
general consumption are unlikely to meet the micronutrient needs
of young children who have fast growth rates yet low food intakes.
The requirements for many micronutrients in children aged 6 to
24 months are not well known and have often been extrapolated
from levels consumed by healthy, older children.[9] As a result,
some estimated requirements may be in excess of the true
requirements and it may be unnecessarily costly to meet them. A
recent meta-analysis [14] concluded that multiple micronutrient
interventions had modest benefits for linear growth among
primarily breastfed infants and young children but the trials have
not addressed non-breastfed infants.
We have conducted a randomised, double-blind, controlled trial
of the efficacy of two locally produced complementary/replace-
ment foods, fortified with different levels of micronutrients, for
infants aged 6 to 18 months. To our knowledge, this is the first
study investigating AFASS foods for infants of HIV-infected
mothers after 6 months, is the largest trial of multiple
micronutrients for children of this age [14], and is a relatively
rare double-blind, controlled trial of a food-based intervention.
Many previous studies have used supplementation approaches
which are generally easier to run and control at the trial stage but
use interventions which may be less easy to implement sustainably
than fortification approaches.
Methods
Study design
The trial is registered as ISRCTN37460449 (www.controlled-
trials.com/mrct). The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. Children were randomised to
one of two locally produced porridges at age 6 months, and were
followed monthly for 12 months. The primary outcome was the
prevalence of stunting at 18 months, chosen since stunting begins
in early infancy, is the most common form of malnutrition in
young children, is largely irreversible, and is associated with long
term poor health and development. The key secondary outcome
was hospital referral or death.
Study population and recruitment
The trial was conducted in Chilenje, Lusaka, Zambia, from
October 2005 to July 2009. Infants were recruited by informing
mothers attending the child health section of the government clinic
on the same site as the project clinic. As over 90% of Lusaka
women bring their infants to the clinic for monthly weighing or
standard early vaccinations, [15] the population hearing about the
study was representative of the area. According to Zambian
government policy, all children receive the following vitamin A
supplements at these ages: 0–5 months and not breastfeeding
15 mg, all children 6–11 months 30 mg, all children 12–59
months 60 mg. Study staff arranged for the 6, 12 and 18 month
doses for study children.
Infants were eligible if they were 6 months +/22 weeks old and in
generally good health and their mothers gave written consent to
attend monthly clinic visits for the next year, feed their infants the
allocated porridge, have their infant undergo project tests including
blood and urine sampling, and have their child tested for HIV at 18
months old. Knowledge of maternal HIV status was not a
requirement for joining the study but 90% of women knew their
status from antenatal HIV antibody testing in the government health
service using the same algorithm described below for project testing.
Randomisation
Randomisation was in blocks of 20; the code was held by the
project Data Safety and Monitoring Board (DSMB). One kg
Table 1. Composition of the trial porridge flours.
Basal fortification
(per kg flour)1
Rich fortification
(per kg flour)2
maize 650 g 615 g
groundnuts 150 g 150 g
bambaranuts 50 g 50 g
beans (white and yellow) 150 g 150 g
energy 4200 kcal 4140 kcal
protein 15% 15%
fat 12% 12%
vitamin A 0.65 RE 6.5 RE
vitamin C 2.0 g
vitamin D 0.1 mg
thiamin (mononitrate) 1.3 mg 9 mg
riboflavin 1.6 mg 11.2 mg
niacin (niacinamide) 13 mg 140 mg
pyridoxine (HCl) 1.6 mg 8.6 mg
folate 0.65 mg 2.21 mg
B12 3.25 mg 9.75 mg
pantothenic acid 40.3 mg
magnesium (oxide) 943 mg
iron (ferrous fumarate)3 6.5 mg 250 mg
zinc (oxide)3 9.75 mg 200 mg
copper (gluconate) 3.2 mg
manganese (sulfate
monohydrate)
12.0 mg
selenium (sodium selenite) 0.2 mg
calcium (CaH(PO4)*2H2O)
3 6.8 g
phosphorus (CaH(PO4)*2H2O) 5.3 g
1Based on estimated amounts of micronutrients which would be available from
50 g porridge flour/day made with maize fortified at levels planned nationally
for Zambia. Overages (usually 10%) added to allow for losses during
processing.
2Based on total estimated micronutrient needs of infants aged 9–11 months
minus amounts expected from low breast milk intakes [9] and assuming intake
of 50g porridge flour/day. Exceptions to the micronutrient levels are that
vitamin C was increased to compensate for low iron bioavailability and zinc
was based on Recommended Daily Allowance set by the International Zinc
Consultative Group. [39] Overages (usually 10%) added to allow for losses
during processing.
3Phytate was analysed in two batches of each flour and averaged 5.8 g/kg. This
translated into phytate:zinc molar ratios of ,19 in the basal flour and ,3.3 in
the richly fortified flour and phytate:iron molar ratios of 5.6 and 1.7 in the two
flours, respectively.
doi:10.1371/journal.pone.0011165.t001
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Figure 1. Flow diagram of participants through the study. All recruited children were included in the analysis of hospital referral and death.
Two children in the richly fortified group who were seen at 18 months had missing length data at that visit and are not included in the analysis of
stunting. 1Reasons for withdrawal up to 12m: basal porridge (N= 46): moved away (15), family against (10), problems with porridge (2), would not
say/other (19); richly fortified porridge (N= 52): moved away (18), family against (10), would not say/other (24). 2Reasons for withdrawal from 12–18m:
basal porridge (N= 30): moved away (13), family against (1), problems with porridge (2), would not say/other (14); richly fortified porridge (N= 27):
moved away (8), family against (1), problems with porridge (1), would not say/other (17).
doi:10.1371/journal.pone.0011165.g001
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bags of porridge flour were labelled with the participant ID
number. At the recommendation of the DSMB, the randomisa-
tion and labelling process was audited halfway through the
study by an independent observer and found to be robust,
accurate and able to maintain blinding of other study staff and
participants.
Infants were allotted to porridges by sequential numbers on
recruitment. Twins (n = 13 pairs) were randomised to the same
diet and included in analyses as separate individuals. There was
one serious protocol violation: during May – June 2007 one
porridge ran out but staff continued to recruit to the other
treatment; the children who were thus not appropriately
randomised were followed for ethical reasons but are not included
in the present analyses.
Study porridges
The two flours, based on maize, beans, bambaranuts and
groundnuts, were similar in bulk ingredients and macronutrient
content but differed in micronutrient content (Table 1). The flours
were mixed with water to make porridges for infant feeding, similar in
consistency and appearance to those in current local use. In pilot
work, porridges were found to be acceptable [16] to the local
population and to displace other micronutrient-poor complementary
or family foods but not to displace breast milk intake [17]. The energy
density of the porridge prepared according to package directions
(equivalent to 30g blended in 250 ml water) was 0.76 kcal/g; [18]
protein represented 16% of energy. The richly fortified porridge
contained micronutrients to meet the World Health Organization
(WHO) estimated needs [9] for infants aged 9–11 months with low
breast milk intake, assuming an intake of 50g flour/day. We did not
include iodine in the micronutrient premix since Zambian salt is
fortified with iodine. The basal porridge had micronutrient levels
which would be produced without any additional fortificants once
maize in Zambia is fortified at the planned level. [10,19]
Micronutrient premixes for both flours were prepared by DSM
(Isando, South Africa). Flour was mixed and processed by extrusion at
Quality Commodities Ltd, Lusaka. Porridge flours were stored for up
to 6 months in a cool, well-ventilated room.
Each batch of flour was analysed by the National Institute for
Scientific and Industrial Research, Lusaka, for macronutrients by
proximate analysis and for iron and zinc by flame atomic
absorption spectroscopy. [20] All batches contained less than the
tolerance levels of aflatoxin ([21]; analyses by Cheetah, Zambia
Ltd, Lusaka, or Polucon, Mombasa, Kenya). Several batches were
also analysed for phytate by HPLC [22] in the laboratory of RSG
at the University of Otago, New Zealand.
Follow-up and adherence
At recruitment, socio-demographic information was obtained
by questionnaire. Weight, adherence, and morbidity were assessed
monthly and length and other anthropometry 3-monthly in the
clinic. Women were given 4 kg of porridge flour each month and
could return for more as required. They were instructed to
prepare the porridge according to the directions on the package,
using a plastic cup, graduated in mL, supplied by the investigators.
Adherence was determined through monthly questioning of
mothers as to how much prepared porridge the child had
consumed (in mL) within each of the two days prior to the visit
and whether consumption on these days was typical. For each
month the mean and standard deviation (SD) reported intake of
the porridge food provided was calculated for ‘typical’ days.
Infants were given adherence scores of 1 (low, ,1 SD below the
mean), 2 (average, 61 SD of the mean), or 3 (high, .1 SD above
the mean). Missed visits were assigned an adherence value of 1.
The values for each month were added in order to calculate a
cumulative adherence score.
Anthropometry
Anthropometric measurements were taken using calibrated equip-
ment and standardized techniques, [23] with children nude or wearing
Table 2. Description of the study population at recruitment.
Basal
porridge
Richly fortified
porridge
N 373 370
Maternal and demographic characteristics
Maternal antenatal HIV status1
Negative 261 (70%) 258 (70%)
Positive 79 (21%) 78 (21%)
Unknown 33 (9%) 34 (9%)
Mother’s age (years) 26.0 (SD 5.7) 26.4 (SD 5.8)
Maternal body mass index (kg/m2)
,18.5 29 (8%) 29 (8%)
18.5–25 225 (61%) 210 (57%)
25–30 76 (20%) 92 (25%)
.30 42 (11%) 39 (11%)
Mother’s education
primary or less 123 (33%) 129 (35%)
secondary 157 (42%) 127 (34%)
college/university 93 (25%) 114 (31%)
Mother’s occupation
housewife 214 (57%) 181 (49%)
salaried employee 61 (16%) 86 (23%)
self-employed 39 (11%) 31 (8%)
other 59 (16%) 72 (20%)
Marital status
married 278 (75%) 279 (75%)
single 79 (21%) 72 (20%)
divorced, separated, widowed 16 (4%) 19 (5%)
Tertiles of socioeconomic status
low 127 (34%) 123 (33%)
middle 151 (40%) 136 (37%)
high 95 (25%) 111 (30%)
Infant characteristics
Sex (#, % F) 182 (49%) 204 (55%)
Birth weight (kg) 3.05 (SD 0.50) 3.05 (SD 0.46)
Weight at 6 months (kg) 7.27 (SD 1.05) 7.28 (SD 1.10)
Length at 6 months (cm) 64.9 (SD 2.3) 64.9 (SD 2.6)
Proportion stunted (length for age
,22 Z)
51 (14%) 40 (11%)
Blood haemoglobin ,105 g/L 140 (38%) 149 (41%)
Breastfeeding duration:
never 22 (6%) 21 (6%)
,6 months 38 (10%) 29 (8%)
breastfeeding at recruitment 313 (84%) 320 (87%)
1Six infants of mothers HIV-uninfected antenatally and one of an HIV-unknown
mother tested HIV-infected by 18 months old.
doi:10.1371/journal.pone.0011165.t002
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a diaper. Maternal weight and height were measured at recruitment
using, respectively, a digital scale (to 100 g) and wall-mounted flexible
tape (to 1 mm). Infant weight was measured on a digital balance (to
10 g) and length on a length board to 1 mm (anthropometry
equipment from Chasmor Ltd, London, UK). Staff conducting
anthropometry were trained by RSG and AMusing a repeat-measures
protocol until they reached an acceptable level of proficiency. [24]
Measurement quality was maintained by achieving acceptable ranges
for both the differences in measurements between the designated
criterion anthropometrist (MC) and the other anthropometrists [24]
and for the total technical error of each measurement. [25]
All anthropometric measurements were done in triplicate and
the median used in analyses. Standard deviation, Z, scores were
calculated using the WHO growth reference data [26] and the
child’s exact age at measurement. Stunting was considered as
length/age Z,22.
Morbidity assessments
At all scheduled and unscheduled visits the clinical officer (JS)
examined children and diagnosed and treated them according to the
Integrated Management of Childhood Illness. [27] Basic care plus
prescription of antibiotics or antimalarials were possible within the
study clinic. Patients were referred either to Chilenje main clinic, where
limited services were available, or to University Teaching Hospital
(UTH), the local tertiary facility, only when exhibiting danger signs
(unable to drink or breastfeed, severe vomiting, convulsions, respiratory
distress, lethargic or unconscious), when requiring surgery, or when
repeatedly presenting with an intractable illness which required
specialist consultation. Diagnoses and treatments in hospital were
determined by doctors not connected with the CIGNIS study;
information about these was available to the project. Referral to
hospital or specialist clinic services was a trial outcome.
Classification and treatment of illness was based on local practice.
If malaria was suspected from history or clinical presentation, a
blood slide was taken and malaria was diagnosed if parasites were
present. Further investigations were carried out in UTH for fevers
without parasites, including lumbar puncture in cases of suspected
meningitis. Diarrhea was defined as at least 3 loose stools or one
bulky watery stool in the past 24 hours. Pneumonia was defined as
history of cough or difficulty breathing plus rapid breathing ($50
breaths/minute for infants and $40 breaths/minute for older
children) with or without subcostal recession.
HIV testing
Serum samples from all children at 18 months were tested for
antibodies to HIV. A serial testing algorithm was used. Samples
were first tested using Determine HIV 1/2 (Inverness Medical,
Japan). If negative, the result is taken to be negative. If positive, a
second test, Unigold HIV 1/2 (Trinity Biotech plc, Ireland), was
used. If positive, the final result is positive but if negative, i.e.
discordant, a third test SD-Bioline HIV 1/2 (Standard Diagnos-
tics, Korea) was used and its result was taken to be the final result.
Iron status
Three indicators of iron status were measured at baseline and
18 months of age. Hemoglobin was measured in fingerprick blood
in by Hemocue (Dronfield, UK). Venous blood was collected in
plain vacutainers, sera separated at UTH within 2 hours,
aliquoted and stored at 280uC. Samples were transported to
London for serum ferritin and transferrin receptor (TRFR) assays.
Ferritin was measured by ELISA [28] using antibodies from
Insight Biotechnology Ltd (Wembley, UK) and Invitrogen Ltd
(Paisley, UK) with standards from Dade Behring (Milton Keynes,
UK). The interassay coefficient of variation (CV) for the standard
(National Institute of Biological Standards and Control, Potters
Bar, UK) was 12%. TRFR was measured by ELISA using a
commercial kit (RAMCO, ATI Atlas, Chichester, UK). The
interassay CVs for the high and low quality control sera were,
respectively, 6.9% and 9.5%. For both assays, external quality
control standards were within expected ranges.
Data management and statistics
Data were double-entered and verified in Access. Range and
logical checks were run in Access and in Stata (Statacorp, College
Station, TX, USA). Stata version 10 was used for all analyses. The
analysis plan was finalised before the trial was unblinded.
Table 3. Indicators of iron status at 6 and 18 months of age among those who completed to 18 months1.
6 Months 18 Months
Basal
porridge
Richly fortified
porridge
Basal
porridge
Richly fortified
porridge
Unadjusted regression coefficient
or Odds ratio (95% CI) P-value
Haemoglobin:
N 285 278 286 282
mean (SD) g/L 108 (12) 107 (14) 107 (13) 112 (11) 5.53 (3.55, 7.51) ,0.001
n (%),105 g/L 103 (36%) 115 (41%) 114 (40%) 63 (22%) 0.43 (0.30, 0.63) ,0.001
Serum Ferritin:
N 270 264 266 262
median (p25, p75) mg/L 13. 2 (6.3, 24.8) 15.2 (7.8, 26.1) 8.7 (5.3, 14.2) 13.6 (9.1, 23.7) 0.49 (0.36, 0.62) ,0.001
n (%),10 mg/L 98 (36%) 80 (30%) 154 (58%) 79 (30%) 0.31 (0.22, 0.45) ,0.001
Serum transferrin receptor:
N 267 263 271 252
median (p25, p75) mg/L 8.1 (6.7, 10.1) 7.9 (6.6, 9.6) 9.6 (7.9, 12.5) 7.9 (6.6, 9.6) –0.27 (–0.33, 20.20) ,0.001
n (%).11 mg/L 48 (18%) 40 (15%) 92 (34%) 35 (14%) 0.31 (0.20, 0.49) ,0.001
1Serum ferritin and transferrin receptor log-transformed for analysis; medians, 25th and 75th percentiles presented. Unadjusted regression coefficients and odds ratios
represent overall differences between treatment arms.
doi:10.1371/journal.pone.0011165.t003
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The impact of richly-fortified porridge on stunting at 18 months
(the primary endpoint) was estimated using odds ratios (OR) and
95% confidence intervals (CI) obtained by logistic regression.
Length-for-age Z score was also analysed as a continuous variable
with differences by linear regression. Severe morbidity, defined as
hospital referral or death, was evaluated using Kaplan-Meier
curves. The impact of the richly-fortified porridge on severe
morbidity was estimated using hazard ratios (HR) and 95% CI
obtained by Cox regression with robust standard errors to account
for repeated referrals within children. Hospital referrals for
planned surgeries (5 circumcisions, 4 hernias, and 4 other
congenital abnormalities) were excluded from the analysis.
All analyses were stratified by maternal HIV status. The
primary analyses of both outcomes were intention to treat and
unadjusted. Maternal education, and socioeconomic status were
considered potential confounders, and were adjusted for in
secondary analyses. Socioeconomic status was measured using
an asset index, created by combining data on possessions and
housing characteristics using principal component analysis. [29]
Since determining optimal feeding of HIV-exposed infants was a
key aim of the study, analyses of children of HIV-infected mothers
were stratified by breastfeeding duration.
Sample size
The sample size calculations assumed a stunting prevalence at
18 months of 40% [30] among children receiving the basal
porridge. Allowing for a 15% loss to follow up, a sample size of
400 per group was estimated to provide .90% power to detect a
30% reduction in the prevalence of stunting, and .80% power to
detect a 25% reduction (alpha= 0.05). The DSMB reviewed the
results twice (September 2007 and May 2008) and, after noting the
prevalence of stunting was lower than anticipated and determining
that an increase in sample size was financially and logistically
impossible, recommended stopping recruitment in mid-July 2008.
Ethics
The study was approved by the ethics committees of the
University of Zambia and the London School of Hygiene and
Tropical Medicine. Mothers gave written informed consent.
Project staff referred participants who were ill to local medical
services and followed up treatments within these services. Neither
funding source (the Bill and Melinda Gates Foundation and DSM
South Africa) was involved in conduct, analysis or interpretation of
the study.
Results
A total of 743 infants were recruited and randomised (Figure 1).
There was a large number of refusals, mostly by women going
away to think about it and not returning.
The trial arms were generally balanced at baseline (Table 2).
Seventy percent of mothers tested HIV-negative antenatally, 21%
tested HIV-positive and 9% did not know or did not wish to
disclose their status. HIV-infected women were older than
uninfected women (28.5 (SD 5.4) versus 25.5 (SD 5.7) years) and
were of slightly lower educational level and socioeconomic status,
although the differences were not significant (data not shown). The
majority (96%) of HIV-uninfected women were breastfeeding at
recruitment, but 38 (24%) of HIV-infected women did not initiate
breastfeeding, and an additional 50 (29%) stopped before the
infant was 6 months old.
There was a 23% loss to follow-up before the infant reached 18
months. All women were contacted by study personnel to ask why
they discontinued in the study. The reasons did not differ by
treatment group and were: child death (12, 7%), did not want to
give a reason (56, 34%), family moved from the study area (54,
32%), family opposition (22, 13%), reported problems with the
study food (5, 3%), other reasons (18, 11%). There were more
HIV-uninfected women among those lost to follow-up (77%) than
among those who completed (68%) but these groups were
otherwise very similar.
The amount of porridge consumed increased with age from
,270 mls/d (,19 g flour/d) at 7 months to ,350 mls/d (,25 g
flour/d) from 11 to 18 months. Neither the number of visits
attended nor adherence differed between treatment groups (OR
(95% CI) for proportion of visits with high adherence in the richly-
fortified compared with the basal diet: 0.79 (0.61, 1.04)). The
proportion of visits with high adherence was significantly greater
among children of HIV-infected women compared with HIV-
uninfected women (OR (95% CI): 1.81 (1.35, 2.41)) and was
significantly lower among children currently breastfed compared
with those not breastfed (OR (95% CI): 0.56 (0.44, 0.70)), those in
Table 4. Factors associated with stunting at 18 months.
N (%)
Unadjusted OR
(95% CI)
Treatment group P= 0.85
Basal porridge 60/290 (20.7%) 1
Richly-fortified porridge 57/284 (20.1%) 0.96 (0.64, 1.44)
Association with other factors
Maternal HIV: P = 0.03
Negative 71/390 (18.2%) 1
Positive 38/133 (28.6%) 1.80 (1.14, 2.83)
Unknown 8/51 (15.7%) 0.84 (0.38, 1.86)
Child HIV: P = 0.46
Negative 112/555 (20.2%) 1
Positive 4/14 (28.6%) 1.58 (0.49, 5.14)
Breastfeeding duration in
HIV negative mothers:
P = 0.02
,12 months 2/41 (4.9%) 1
12–17 months 37/199 (18.6%) 4.45 (1.03, 19.28)
18+ months 32/.150 (21.3%) 5.29 (1.21, 23.08)
Breastfeeding duration in
HIV positive mothers:
P = 0.44
Never 8/34 (23.5%) 1
,6 months 15/44 (34.1%) 1.68 (0.61, 4.61)
6+ months 15/55 (27.3%) 1.22 (0.45, 3.28)
Socioeconomic status: P,0.001
Low 61/185 (33.0%) 1
Middle 38/226 (16.8%) 0.41 (0.26, 0.65)
High 18/163 (11.0%) 0.25 (0.14, 0.45)
Mother education: P,0.001
Primary or less 63/181 (34.8%) 1
Secondary 38/228 (16.7%) 0.37 (0.24, 0.60)
College/university 16/165 (9.7%) 0.20 (0.11, 0.37)
Stunted at baseline: P,0.001
No 62/501 (12.4%) 1
Yes 54/72 (75.0%) 21.25 (11.70, 38.55)
doi:10.1371/journal.pone.0011165.t004
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the highest socioeconomic status quintile compared with the lowest
(OR (95% CI): 0.51 (0.34, 0.76)) and those whose mothers had
college education compared with primary education or less (OR
(95% CI): 0.63 (0.44, 0.91)).
The richly-fortified porridge increased haemoglobin between 6
and 18 months, and prevented the deterioration in iron status
assessed by serum ferritin or transferrin receptors seen in the basal
porridge group (Table 3). Similar effects were seen for children of
HIV-infected and uninfected and in those breastfed or not at
recruitment (data not shown). Adherence was associated with these
improvements in iron status in the richly-fortified porridge group
(data not shown).
Children of HIV-infected women had a higher prevalence of
stunting at 18 months (33/133, 29%) than children of HIV-
uninfected women (71/390, 18%; OR 1.80; 95% CI 1.14, 2.83;
P = 0.03). Breastfeeding duration was not associated with
stunting at 18 months. Children in the lowest socioeconomic
group, those with mothers with only primary education, and
those stunted at baseline were more likely to be stunted at 18
months (Table 4). Treatment did not affect stunting or mean
length-for-age Z score at 18 months overall, nor when stratified
by maternal antenatal HIV status (Table 5). After controlling for
baseline length-for-age Z score, socioeconomic status and
maternal education, indices of linear growth were significantly
increased by treatment among children of HIV-infected women
breastfed for less than 6 months; higher adherence was
associated with greater benefit. Inclusion of only known HIV-
uninfected children did not change this result.
Table 5. Effect of porridge group on prevalence of stunting (length-for-age Z,22) and mean length-for-age Z scores at 18
months.1
Basal porridge
Richly
fortified
porridge
Unadjusted regression
coefficient or Odds ratio
(95% CI) p-value
Adjusted2 regression
coefficient or Odds
ratio (95% CI) p-value
All children:
N 290 284
n (%) stunting 60 (20.7%) 57 (20.1%) 0.96 (0.64, 1.44) 0.85 0.87 (0.50, 1.53) 0.63
mean (SD) length/age Z 21.12 (1.11) 21.05 (1.20) 0.08 (20.11, 0.27) 0.42 0.04 (20.07, 0.15) 0.47
Stratified by maternal HIV status3:
Negative:
N 194 196
n (%) stunting 36 (18.6%) 35 (17.9%) 0.95 (0.57, 1.60) 0.86 0.92 (0.45, 1.88) 0.82
mean (SD) length/age Z 21.07 (1.04) 20.94 (1.22) 0.14 (20.09, 0.36) 0.24 0.07 (20.06, 0.21) 0.30
Positive:
N 70 63
n (%) stunting 21 (30.0%) 17 (27.0%) 0.86 (0.41, 1.84) 0.70 0.41 (0.13, 1.26) 0.12
mean (SD) length/age Z 21.36 (1.25) 21.38 (1.16) 20.02 (20.44, 0.39) 0.91 0.17 (20.07, 0.42) 0.17
Mother HIV positive, stratified by3:
Breastfeeding ,6 months:
N 43 35
n (%) stunting 15 (34.9%) 8 (22.9%) 0.55 (0.20, 1.52) 0.24 0.17 (0.04, 0.85) 0.03
mean (SD) length/age Z 21.40 (1.34) 21.23 (1.28) 0.18 (20.42, 0.77) 0.56 0.40 (0.05, 0.75) 0.02
Breastfeeding $6 months:
N 27 28
n (%) stunting 6 (22.2%) 9 (32.1%) 1.66 (0.50, 5.53) 0.41 1.10 (0.16, 7.53) 0.92
mean (SD) length/age Z 21.28 (1.13) 21.57 (0.97) 20.29 (20.86, 0.28) 0.31 20.04 (20.38, 0.31) 0.84
Mother HIV positive, child HIV negative, stratified by3:
Breastfeeding ,6 months:
N 41 32
n (%) stunting 14 (35.2%) 8 (25.0%) 0.64 (0.23, 1.80) 0.40 0.20 (0.04, 0.98) 0.048
mean (SD) length/age Z 21.36 (1.29) 21.21 (1.34) 0.15 (20.47, 0.77) 0.63 0.44 (0.08, 0.80) 0.02
Breastfeeding $6 months:
N 25 27
n (%) stunting 5 (20.0%) 9 (33.3%) 2.00 (0.56, 7.09) 0.28 3.61 (0.35, 37.32) 0.28
mean (SD) length/age Z 21.22 (1.14) 21.60 (0.98) 20.39 (20.98, 0.20) 0.20 20.20 (20.55, 0.15) 0.26
1Two children, both in the richly fortified arm, were missing length data at 18 months.
2Adjusted for baseline (6 month) length-for-age Z score, asset index score, and maternal education.
3No subgroup analyses are presented for HIV-unknown mothers because there were mixed reasons for lack of HIV testing. Stratification by breastfeeding duration was
done only for HIV-exposed children since this is the group for which an evidence base is required for policy.
doi:10.1371/journal.pone.0011165.t005
Micronutrient Fortification
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11165
Twelve children died, all in hospital: 7 in the basal porridge
group and 5 in the richly-fortified porridge group. Causes of death
were: 4 pneumonia, 3 diarrhea, 1 tuberculosis, 1 malaria, 1
meningitis, 1 anemia, 1 choking due to epileptic convulsions.
Three of those in the basal group and all 5 in the richly-fortified
group had HIV-infected mothers. Only one child could be
HIV-tested before death and was found positive. Nine infants of
mothers HIV-infected antenatally, 6 infants of mothers negative
antenatally and two infants whose mother’s status was unknown
tested positive themselves.
There were 69 referrals among 64 (17%) children in the basal
diet group and 81 referrals among 65 (17%) children in the richly
fortified diet group (Table 6). In both groups, 91% of referrals
were in-patient admissions. The causes of referral were similar in
the two porridge groups except that there were slightly fewer for
malaria (HR=0.63; 95% CI 0.32, 1.24; p = 0.18) and significantly
more for pneumonia (HR=2.68, 95% CI= 1.17–6.11, p= 0.02)
in the richly-fortified group. Trial arm had no significant effect
overall on the rate of total referrals (Table 7 and Figure 2). Similar
results were seen if time to first referral only was analysed (data not
shown). There was a trend towards increased referrals among
children of HIV-infected mothers in the richly-fortified group,
although this did not reach statistical significance. This trend
appeared to be mostly due to effects in children who were HIV-
infected, but appeared independent of breastfeeding duration.
Discussion
Provision from ages 6 to 18months of a micronutrient-rich fortified
porridge flour, formulated to meet all nutritional requirements
according to current best estimates [9] was successful in improving
children’s iron status. This translated into modest improvements in
linear growth amongst the subgroup of children of HIV-infected
mothers who stopped breastfeeding before 6 months but had no effect
Table 6. Hospital referrals and deaths by porridge group.
Basal diet
Richly
fortified diet
N 373 370
Deaths (% of all children) 7 (1.9%) 5 (1.4%)
Known HIV positive (% of all children) 9 (2.4%) 8 (2.2%)
Children with 1 or more referrals: 64 (17.2%) 65 (17.6%)
Total number of referrals1 69 81
Diagnoses (total referrals, % of referrals; % of all children2)
All children:
Malaria 24 (34.8%; 5.9%) 15 (18.5%; 3.8%)
Acute diarrhea 16 (23.2%; 4.3%) 17 (21.0%; 4.3%)
Pneumonia 8 (11.6%; 2.1%) 21 (25.9%; 5.1%)
Skin infections 3 (4.4%; 0.8%) 6 (7.4%; 1.4%)
Other3 18 (26.1%; 4.6%) 22 (27.2%; 4.9%)
Children of HIV-uninfected women4:
N 261 258
Children with 1 or more referrals 42 39
Total number of referrals 46 45
Malaria 15 (32.6%; 5.0%) 5 (11.1%; 1.9%)
Acute diarrhea 13 (28.3%; 5.0%) 11 (24.4%; 4.3%)
Pneumonia 5 (10.9%; 1.9%) 11 (24.4%; 4.3%)
Skin infections 1 (2.2%; 0.4%) 3 (6.7%; 1.2%)
Other3 12 (26.1%; 4.2%) 15 (33.3%; 4.7%)
Children of HIV-infected women4:
N 79 78
Children with 1 or more referrals 18 22
Total number of referrals 19 32
Malaria 6 (31.6%; 7.6%) 8 (25.0%; 9.0%)
Acute diarrhea 3 (15.8%; 3.8%) 6 (18.7%; 6.4%)
Pneumonia 3 (15.8%; 3.8%) 8 (25.0%; 7.7%)
Skin infections 1 (5.3%; 1.3%) 3 (9.4%; 2.6%)
Other3 6 (31.6%; 7.6%) 7 (21.9%; 7.7%)
1Includes 137 inpatient hospital admissions and 13 (6 in the basal group and 7 in the richly-fortified group) referrals to specialist outpatient clinics.
2Percent of children with at least one referral for each diagnosis. Note total number of referrals includes instances of more than one referral in some children.
3Includes other infections, severe anemia, accidental injury and congenital conditions but excludes elective surgery.
4No subgroup analyses are presented for HIV-unknown mothers because there were mixed reasons for lack of HIV testing.
doi:10.1371/journal.pone.0011165.t006
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on linear growth or hospital referral of the group as a whole. Among
children of HIV-infected mothers, there was a non-significant trend
towards increased referrals in the richly-fortified arm.
The population has clear evidence of deficiencies in iron and
vitamin A, as determined in this and previous work [11].
Therefore, an effect of the richly-fortified porridge on iron status
is important. It is interesting that this was achieved even though
children’s intake of porridge was only about half the estimate used
for determining the micronutrient levels in the richly-fortified
porridge. The porridge was also generally prepared more dilute
than given in the instructions but, based on the pilot study for the
trial [17], calories were not the limiting factor in these children’s
diets and increasing porridge energy density using a-amylase did
not affect growth.
All children were provided with porridge and medical care which
could be why the overall stunting rate was lower than the 40% [30]
used in sample size estimates. This 40% rate is consistent with the
36% stunting we measured among Chilenje clinic children aged 18
months who were not part of the CIGNIS study because they
reached 6 months old before the recruitment period but were
otherwise similar. The risk of stunting among study children
compared with clinic children was: OR 0.46; 95% CI 0.25, 0.87;
P= 0.007. Therefore, effects of rich fortification, compared with
basal, on stunting may have been hard to detect. This problem has
been seen in other food-based intervention trials [31] in low income
countries where providing the control group with food is essential
both ethically and logistically, i.e. to ensure equivalent compliance
between groups. Low stunting prevalence could also have resulted
from biased recruitment due to a refusal rate which was higher than
expected, based on our previous study in Chilenje. However, we
determined that birth weights of CIGNIS children were virtually
identical to those of the total population of infants born in Chilenje
clinic during the same period (data not shown).
Importantly, the overall rate of hospital referral plus death did
not differ between treatment groups. In the richly-fortified
porridge group, there were no mortalities among infants of
HIV-negative mothers. Among HIV-exposed children, there was a
non-significant trend toward increased referrals in the richly-
fortified group, with only pneumonia referrals increased. The
subgroup analysis by maternal HIV status was planned because of
its policy relevance but numbers were small; thus, the trend may
be from chance and should be interpreted with caution. If not
chance, possible explanatory factors include: an immune recon-
stitution syndrome [32] which could lead to increased respiratory
symptoms; increased respiratory symptoms as have been previ-
ously observed following vitamin A supplementation [33] but not
fortification; folate antagonism of the cotrimoxazole [34] which
the all children of HIV-infected mothers were given as standard of
care; operational issues regarding differential diagnoses resulting
from improved prevention and treatment of malaria. [35] Adverse
effects of iron on malaria, as reported with iron supplementation of
Tanzanian children, [12] are unlikely since there were fewer
malaria referrals for children given the richly-fortified porridge.
Other infections may also be increased following iron supplemen-
tation of non-deficient children [12] but we are not aware of
studies showing increased illness with iron fortification. Since
micronutrient fortification is a key part of prevention of
micronutrient deficiencies globally,[36] factors leading to hospital
referral among this population are important and are under
further investigation.
Although antiretroviral prophylaxis can reduce HIV transmis-
sion during early lactation [6] and although HIV-infected infants
should continue breastfeeding [5], optimal feeding practises for
HIV-exposed, uninfected infants over 6 months is a current
concern for policy and practice. In our study, among middle class
urban HIV-infected women with access to treated water and good
Table 7. Hazard ratios for referral to hospital or death; richly-fortified porridge group compared to basal porridge group1.
Referrals/person-yrs (rate per 100 pyrs) HR (95% CI) P
Basal porridge Richly fortified porridge
All children 69/322 (21.4) 81/318 (25.5) 1.19 (0.85, 1.68) 0.31
Stratified by:
Maternal HIV status1:
Negative 46/219 (21.0) 45/217 (20.8) 0.99 (0.65, 1.52) 0.98
Positive 19/75 (25.5) 32/72 (44.8) 1.76 (0.95, 3.26) 0.07
HIV-positive mothers, stratified by:
Child HIV status:
Negative 14/66.2 (21.1) 14/59.7 (23.5) 1.12 (0.55, 2.29) 0.75
Positive or unknown3 5/8.3 (60.3) 18/11.8 (152.5) 2.45 (0.87, 6.90) 0.09
Breastfeeding duration2:
,6 months 11/45.8 (24.0) 14/37.7 (37.2) 1.56 (0.70, 3.50) 0.28
$6 months 8/28.7 (27.9) 18/33.8 (53.2) 1.92 (0.75, 4.90) 0.18
HIV-negative children of positive mothers, stratified by:
Breastfeeding duration2:
,6 months 7/42.2 (16.6) 8/32.6 (24.5) 1.50 (0.57, 4.00) 0.41
$6 months 7/24.0 (29.2) 6/27.0 (22.2) 0.76 (0.27, 2.14) 0.60
1No subgroup analyses are presented for HIV-unknown mothers because there were mixed reasons for lack of HIV testing.
2Stratification by breastfeeding duration was done only for HIV-exposed children since this is the group for which an evidence base is required for policy.
3HIV status could not be determined for most children who died and for those who did not complete the study; they are included in the HIV-positive or unknown
group.
doi:10.1371/journal.pone.0011165.t007
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medical care, there was no overall effect of breastfeeding after 6
months on stunting. Provision of the richly-fortified porridge
improved linear growth among non-breastfed infants of HIV-
infected mothers. A recently published study also from Lusaka
found growth faltering, as measured by weight-for-age, among
children whose HIV-infected mothers stopped breastfeeding early
Figure 2. Kaplan-Meier estimates of survivor function for hospital referral or death. All 12 deaths occurred in hospital. Dropouts were
censored at the date of last project visit. Admitted children became at risk again on discharge from hospital. In Figure 2b. ‘neg’ =HIV-uninfected
mother; ‘pos’ = HIV-infected mother; HIV-unknown women are not included. There were no significant differences by treatment either overall
(P = 0.31) or within maternal HIV status groups (P = 0.98 for children of HIV-negative mothers and P= 0.07 for children of HIV-positive mothers).
doi:10.1371/journal.pone.0011165.g002
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but no such faltering as measured by length-for-age. [37] Given
the effects on linear growth we found among HIV-exposed
children breastfed ,6 months, it is likely relevant that we used
considerably higher fortificant levels for the richly-fortified
porridge than were in the maize blend cereal provided in the
other study.
In summary, the rich micronutrient fortification did not reduce
stunting or hospital referral but did improve iron status and reduce
anemia. For the large proportion of HIV-infected mothers who
stopped breastfeeding before 6 months, the richly micronutrient-
fortified porridge may be a choice which could benefit their
children’s linear growth. However, the major effects on stunting
appear to have resulted from factors, possibly improved health
care, associated with participation in the study, as has been seen
elsewhere [38], not from higher intake of micronutrients.
Supporting Information
Checklist S1 CONSORT checklist.
Found at: doi:10.1371/journal.pone.0011165.s001 (0.11 MB
PDF)
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0011165.s002 (0.06 MB
PDF)
Acknowledgments
We are grateful to Quality Commodities, Lusaka, especially production
manager, Mr. Chongo, for preparing and storing the flours; to the Data
Safety and Monitoring Board – Dr. Paul Kelly, Dr. Jim Todd, Dr. Nigel
Rollins – for their considered efforts to monitor and support the trial; to
Max Katubulushi, UTH, for audit of the diet randomisation and
distribution processes, and to Gabi Meineke, LSHTM, for help with
financial and logistic management. We are particularly grateful to the
mothers and children who participated in the study and to the staff of
Lusaka District Health who permitted and supported the study.
The members of the CIGNIS study team are:
Principal Investigator: Suzanne Filteau, London School of Hygiene and
Tropical Medicine (LSHTM), UK;
Zambian Lead Investigator: Lackson Kasonka, University Teaching
Hospital (UTH), Lusaka, Zambia;
Senior Investigators: Rosalind Gibson, University of Otago, New Zealand;
Ursula A. Gompels, LSHTM; Shabbar Jaffar, LSHTM; Emmanuel
Kafwembe, Tropical Diseases Research Centre, Ndola; Mwaka Monze,
UTH; Moses Sinkala, Catholic Relief Services, Zambia; Andrew Tomkins,
Institute of Child Health, University College, London, UK; Rodah Zulu,
National Institute of Science and Industrial Research, Lusaka, Zambia;
Clinic Coordinator: Molly Chisenga;
Clinical Officer: Joshua Siame;
Data Manager: Hildah Banda Mabuda;
Statisticians: Kathy Baisley, Helen Dale, Andrea Rehman;
Research Fellows: Matthew Bates, Anne Mullen;
Clinic Staff: Hellen Kangwa Bwalya, Margaret Chileshe, Priscilla Kangwa
Kowa, Mabvuto Kumwenda, Munalula Likando, Sydney Mambwe,
Mutinta Muzyamba, Anne Mwale, Lungowe Nyaywa;
Laboratory Staff: Mirriam Kapambwe, Humphrey Bima, Laura Gosset,
Louise Hackett, Abigail Jackson, Eric Njunju, Sydney Mwanza;
Data Entry: Natalia Shampwaya, Concillia Kabanga;
Drivers and Cleaners: John Chobo, Winford Kapumba, Charity Musonda,
Philip Soko.
Author Contributions
Conceived and designed the experiments: TCSTN SF. Performed the
experiments: TCSTN. Analyzed the data: TCSTN. Contributed reagents/
materials/analysis tools: TCSTN. Wrote the paper: TCSTN SF.
References
1. Shrimpton R, Victora C, de Onis M, Lima R, Blo¨ssner M, et al. (2001)
Worldwide timing of growth faltering: implications for nutritional interventions.
Pediatrics 107: e75.
2. World Health Organization (2001) The optimal duration of exclusive
breastfeeding.
3. World Health Organization (2002) Complementary feeding: Summary of
guiding principles for complementary feeding of the breastfed child.
4. Filteau S (2009) The HIV-exposed, uninfected African child. Trop Med Int
Health 14: 276–287.
5. World Health Organization (2007) HIV and infant feeding: update.
6. Mofenson L (2009) Prevention of breast milk transmission of HIV: the time is
now. JAIDS 52: 305–308.
7. World Health Organization (2005) Guiding principles for feeding non-breastfed
children 6–24 months of age.
8. Lunney K, Jenkins A, Tavengwa N, Majo F, Chidhanguro D, et al. (2008) HIV-
positive poor women may stop breast-feeding early to protect their infants from
HIV infection although available replacement diets are grossly inadequate.
J Nutr 138: 351–357.
9. Dewey K, Brown K (2003) Update on technical issues concerning
complementary feeding of young children in developing countries and
implications for intervention programs. Special issue based on a World Health
Organization expert consultation on complementary feeding. Food Nutr Bull
24: 5–28.
10. Famine Early Warning Systems Network (2006) Zambia Food Security Update.
11. Gitau R, Makasa M, Kasonka L, Sinkala M, Chintu C, et al. (2005) Maternal
micronutrient status and decreased growth of Zambian infants born during and
after the maize price increases resulting from the Southern African drought of
2001–2002. Pub Health Nutr 8: 837–843.
12. Sazawal S, Black R, Ramsan M, Chwaya H, Stoltzfus R, et al. (2006) Effects of
routine prophylactic supplementation with iron and folic acid on admission to
hospital and mortality in preschool children in a high malaria transmission
setting: community-based, randomised, placebo-controlled trial. Lancet 367.
13. Serlemitsos J, Fusco H (2001) Vitamin A Fortification of Sugar in Zambia
1998–2001.
14. Ramakrishnan U, Nguyen P, Martorell R (2009) Effects of micronutrients on
growth of children under 5y of age: meta-analyses of single and multiple nutrient
interventions. Am J Clin Nutr 89: 191–203.
15. World Health Organization, UNICEF (2009) Review of National Immunization
Coverage 1980–2008: Zambia.
16. Owino V, Sinkala M, Amadi B, Tomkins A, Filteau S (2007) Acceptability,
storage stability and costing of alpha-amylase-treated maize-beans-groundnuts-
bambaranuts complementary blend. J Sci Food Agriculture 87: 1021–1029.
17. Owino VO, Kasonka LM, Sinkala MM, Wells JK, Eaton S, et al. (2007)
Fortified complementary foods with or without alpha-amylase treatment
increase hemoglobin but do not reduce breast milk intake of 9-mo-old Zambian
infants. Am J Clin Nutr 86: 1094–1103.
18. Owino V, Kasonka L, Sinkala M, Wells J, Eaton S, et al. (2007) Fortified
complementary foods, with or without a-amylase-treatment, increase hemoglo-
bin but do not reduce breast milk intake of 9-month old Zambian infants.
Am J Clin Nutr 86: 1094–1103.
19. MOST (2005) Fortification Basics: maize flour/meal.
20. AOAC (1995) Official Methods of Analysis (16th edn). Arlington, USA: AOAC.
International.
21. Dohlman E (2003) Mycotoxin Hazards and Regulations: Impacts on Food and
Animal Feed Crop Trade. In: Jean Buzby e, ed. International Trade and Food
Safety: Economic Theory and Case Studies; Agricultural Economic Report 828:
USDA.
22. Lehrfield J (1989) High-performance liquid chromatography analysis of phytic
acid on a pH-stable, macroporous polymer column. Cereal Chemistry 66:
510–515.
23. Lohman T, Roche A, Martorell R (1988) Anthropometric standardization
reference manual. Champaign, USA: Human Kinetics Publications.
24. Zerfas A (1985) Checking continuous measures: Manual for Anthropometry. Los
Angeles, USA: Division of epidemiology, School of Public Health, University of
California.
25. Ulijaszek S, Kerr D (1999) Anthropometric measurement error and the
assessment of nutritional status. Br J Nutr 82: 165–177.
26. World Health Organization (2006) Child growth standards.
27. World Health Organization (1998) IMCI information packet. Geneva:
Department of Child and Adolescent Health and Development, WHO/CHS/
CAH/98.1D. Geneva: WHO.
28. Beesley R, Filteau S, Tomkins A, Doherty T, Ayles H, et al. (2000) Impact of
acute malaria on plasma transferrin receptor concentrations. Trans Roy Soc
Trop Med Hyg 94: 295–298.
29. Filmer D, Pritchett L (2001) Estimating wealth effects without expenditure data
– or tears: an application to educational enrolments in states of India.
Demography 38: 115–132.
30. World Health Organization (2002) Online statistics.
Micronutrient Fortification
PLoS ONE | www.plosone.org 11 June 2010 | Volume 5 | Issue 6 | e11165
31. Lartey A, Manu A, Brown KH, Peerson JM, Dewey KG (1999) A randomized,
community-based trial of the effects of improved, centrally processed
complementary foods on growth and micronutrient status of Ghanaian infants
from 6 to 12 mo of age. Am J Clin Nutr 70: 391–404.
32. Sun H-Y, Singh N (2009) Immune reconstitution inflammatory syndrome in
non_HIV immunocompromised patients. Curr Opinion Infect Dis 22: 394–402.
33. Chen H, Zhuo Q, Yuan W, Wang J, Wu T (2008) Vitamin A for preventing
acute lower respiratory tract infections in children up to seven years of age.
Cochrane Database Syst Rev. CD006090.
34. Safrin S, Lee B, Sande M (1994) Adjunctive folinic acid with trimethoprim-
sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is
associated with an increased risk of therapeutic failure and death. J Infect Dis
170: 912–917.
35. Chanda P, Hamainza B, Mulenga S, Chalwe V, Msiska C, et al. (2009) Early
results of integrated malaria control and implications for the management of
fever in under-five children at a peripheral health facility: a case study of
Chongwe rural health centre in Zambia. Malaria Journal. 49 p.
36. Allen L, de Benoist B, Dary O, Hurrell R, eds. (2006) Guidelines on food
fortification with micronutrients: World Health Organization, Food and
Agriculture Organization.
37. Arpadi S, Fawzy A, Aldrovandi G, Kankasa C, Sinkala M, et al. (2009) Growth
faltering due to breastfeeding cessation in uninfected children born to HIV-
infected mothers in Zambia. Am J Clin Nutr 90: 344–353.
38. Fillol F, Cournil A, Cames C, Sokhna C, Simondon KB (2010) Active malaria
morbidity management has limited impact on height status of preschool
senegalese children. J Nutr 140: 625–629.
39. International Zinc Nutrition Consultative Group (2004) Assessment of the Risk
of Zinc Deficiency in Populations and Options for its Control. Food Nutr Bull
25: 94S–203S.
Micronutrient Fortification
PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e11165
